Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Evotec : and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto

share with twitter share with LinkedIn share with facebook
share via e-mail
09/14/2017 | 08:10am CET

  • LAB150 is a joint effort by MaRS Innovation and Evotec
  • Selection and acceleration of early-stage drug discovery projects originating from leading academic institutions and teaching hospitals in Toronto (Canada)

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation ("MI") today announced the launch of "LAB150". This transformational Toronto-based partnership will give Canadian academic institutions and teaching hospitals access to the world-class infrastructure and drug discovery expertise of Evotec and pair it with cutting-edge drug discovery projects emerging from the 15 member institutions of MaRS Innovation.

A crucial lack of the funding, specialised infrastructure and drug development expertise necessary to translate disease-related biological pathways into focused drug discovery programmes has been a persistent hindrance for promising biomedical research to reach clinical development and the marketplace in Canada and globally. LAB150 addresses precisely this challenge. The goal of this new partnership is to significantly shorten the drug discovery timeline and to generate viable start-up companies with high potential for success.

MI will identify projects and build technical and business cases from scientific concepts that focus on first-in-class and disease-related novel biological pathways. Evotec will contribute infrastructure and pre-clinical drug development expertise to translate such discoveries into potential medicines.

Dr Rafi Hofstein, President & CEO of MI, said: "LAB150 represents an extraordinary opportunity for Canada to bridge the drug discovery gap with the objective of stimulating the formation of new ventures in downtown Toronto and of developing ground-breaking therapies to benefit Canadians and others around the world." Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are delighted to expand our Academic BRIDGE network and partnerships together with MaRS Innovation. The dramatic reduction of search costs for capital for the first translational work packages of academic science, early validation of experiments, and industry-proven drug discovery processes will add a highly valuable new tool to the Canadian ecosystem of innovation."

Evotec is seeking partnerships across all biotechnology innovation hubs and has selected MI and Toronto as a top-notch venue for its first North American partnership. This is a testament not only to MI's novel approach to commercialisation but also to the quality of science and innovation of MI's member institutions. Supported by financial contributions from both MI and Evotec, this newly formed five-year partnership will accelerate the development and commercialisation of Canadian-born therapies delivered globally. MI and Evotec are already collaborating on other projects, notably Fibrocor Therapeutics LP, a company based in Toronto, which focuses on developing first-in-class therapeutics targeting fibrotic diseases.

The name of this partnership, LAB150, commemorates Canada's 150th anniversary.

About MaRS

Innovation MaRS Innovation is the commercialization agent for 15 of Ontario's leading academic institutions including the University of Toronto and its affiliated research hospitals, York University, and Ryerson University. Supported by the Government of Canada through the Networks of Centres of Excellence, by the Government of Ontario through the Ontario Centres of Excellence, and by its members, MaRS Innovation is a transformational partnership that turns research strengths into commercial opportunities through industry partnerships, licensing and company creation. MaRS Innovation represents over $1.47 billion of R&D funding annually, a portfolio of 60 companies, $160M in outside risk capital, and is credited with creating over 400 jobs. For more information please visit www.marsinnovation.com.

About Evotec AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer in the field of tissue fibrosis. For additional information please go to www.evotec.com.


Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Language:   English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EVOTEC AG
02:05pEVOTEC : To report fiscal year 2017 results on 28 march 2018
03/14EVOTEC AG : Preliminary announcement of the publication of quarterly reports and..
03/14EVOTEC AG : Preliminary announcement of the publication of financial reports acc..
03/14EVOTEC : and Sanofi in exclusive talks to create an Evotec-led Infectious Diseas..
03/09SANOFI : turns infectious R&D over to Evotec
03/09SANOFI : EvoTec to command vast Sanofi resources in infectious disease R&D partn..
03/08EVOTEC : and Sanofi in Exclusive Talks to Create an Evotec-Led Infectious Diseas..
03/08SANOFI : in Exclusive Talks with Evotec to Create R&D Platform
03/08EVOTEC : and Sanofi in exclusive talks to create an Evotec-led Infectious Diseas..
03/08EVOTEC : And sanofi in exclusive talks to create an evotec-led infectious diseas..
More news
News from SeekingAlpha
03/09Evotec (EVTCY) Investor Presentation - Slideshow 
03/08Evotec set to take on Sanofi's infectious disease research unit 
2017Evotec enters into research collaboration with CRTD to discover therapies for.. 
2017Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare Conference - Slid.. 
2017Evotec's (EVOTF) CEO Werner Lanthaler on Q3 2017 Results - Earnings Call Tran.. 
Financials (€)
Sales 2017 249 M
EBIT 2017 41,6 M
Net income 2017 32,5 M
Debt 2017 97,5 M
Yield 2017 -
P/E ratio 2017 67,87
P/E ratio 2018 50,90
EV / Sales 2017 9,76x
EV / Sales 2018 7,54x
Capitalization 2 328 M
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,0 €
Spread / Average Target 21%
EPS Revisions
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG18.56%2 856
CELLTRION, INC.--.--%37 685
LONZA GROUP-10.25%18 428